Barton is exactly right. This trial is taking cancer patients with literarily no hope at all; folks who have failed 3 protocols including the latest and greatest (and it is great) Keytruda! These poor patients are literally counting their last days on Earth and TCRT is shrinking their tumors in an early stage safety study.
Once TCRT has an opportunity to tinker with the science, ie using MB-IL15, IL-2 and other enhancements this treatment has the ability to quite literally be an off the shelf first line option for millions of patients. Recall Dr. Cooper said this years ago, and although he wasn't the brightest CEO he surely is one of the smartest cancer researchers ever.
I think BP will take notice and wouldn't be surprised to see partnership and/or takeover offers in the next few months.